companies / sanegenebio-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-06-16 json
| total_raised | 118,000,000118.0M | ○ |
|---|---|---|
| founded | 2021 | |
| hq | Woburn, United States | |
| industry | unknown | |
| stage | series-b+ |
Sanegene Bio makes RNAi medicines for obesity, cardiometabolic, and autoimmune diseases using the LEAD system to direct gene-silencing payloads to liver, fat, muscle, and immune cells. Silencing disease genes across multiple tissue types from a single subcutaneous injection surpasses the liver-only targeting of earlier RNAi platforms.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-12-01 | series-b | 110,000,000110.0M | null | ○ |
unreachable
| fact | status | src |
|---|---|---|
| Series B, $110.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |